Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 13/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7089384 | 0.75 | ALDH1A1 (0.39) | ALDH1A1GAA | |
| SCHEMBL12370392 | 0.74 | CCR1 (0.43) | CCR1CCR5CCR8HDAC6S1PR3 | |
| SCHEMBL29692311 | 0.74 | CCR1 (0.43) | CCR1CCR5CCR8HDAC6S1PR3 | |
| SCHEMBL14396440 | 0.72 | NOS3 (0.42) | CCR1CCR5CCR8HDAC6S1PR3 | |
| SCHEMBL11097043 | 0.71 | ATM (0.43) | — | |
| SCHEMBL16545967 | 0.70 | HTT (0.37) | CCR1CCR8HDAC6NOS3NOS2 | |
| SCHEMBL11041678 | 0.70 | GAA (0.35) | ALDH1A1GAA | |
| SCHEMBL17321032 | 0.68 | GAA (0.31) | GAA | |
| SCHEMBL25678496 | 0.67 | CCR1 (0.43) | CCR1CCR5CCR8HDAC6S1PR3 | |
| SCHEMBL11041825 | 0.67 | GAA (0.44) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | CCR1 666/4885CCR5 1465/4885CCR8 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.